A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer

Summary

This is an open-label, single arm, multi-stage, phase II trial of Trifluridine/tipiracil as a palliative treatment for patients with metastatic triple negative breast cancer who have failed both a taxane and anthracycline or have contraindications to these agents.

Timeline

Start

2020-02

Primary completion

2020-06-09

Completion

2020-06-09

Outcome

Outcome not reported

Stopped: “Sponsor withdrew support”

Drugs

Indications